Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now
Relmada Therapeutics (NASDAQ:RLMD) reported Q1 2026 results on May 12, citing positive 12-month Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, with a 95% complete response rate, according to the company. It said it has $234 million cash and a $160 million financing, expected to fund operations through 2029, including a Phase 3 RESCUE program starting mid-2026.
How this was made
The 30-second read
Why it matters
The disclosed Phase 2 efficacy, cash runway through 2029, and patent-protection extension potential are supportive for sentiment, but the piece is framed as a “best growth stocks” list and does not clearly add brand-new information beyond the already-referenced Q1 results.
Market read
Traders may monitor for incremental updates around AUA presentations and any confirmation of Phase 3 design/enrollment milestones, but the article itself is largely promotional.
What to watch
The article does not provide Phase 3 primary endpoints, comparator strategy, enrollment size, or prior trial limitations—key drivers of Phase 3 risk that traders would need for sizing and timing.
Background
Relmada Therapeutics is a clinical-stage biotech developing NDV-01 for high-risk non-muscle invasive bladder cancer; the article references Q1 2026 results and upcoming Phase 3 RESCUE.
Ticker impact
Relmada reports Q1 2026 results with positive 12-month Phase 2 NDV-01 data (95% complete response) and plans to start Phase 3 RESCUE mid-2026.
Moderate upside bias around conference/Phase 3 execution expectations; magnitude likely limited because the article is promotional and lacks fresh, newly disclosed datapoints beyond the cited results.
The text cites specific clinical efficacy (95% complete response), cash balance ($234M), and a mid-2026 Phase 3 start, but it reads like a best-stocks promo and does not clearly indicate this is a newly released disclosure today.
Market effects
Reinforces risk-on sentiment for small-cap clinical-stage biotech with bladder cancer assets, but provides no cross-company regulatory or trial read-across.
No clear regional market linkage beyond US small-cap biotech interest.
Limited; the story is company-specific clinical and financing execution.
Counterpoint
A single Phase 2 efficacy headline (even with a high complete response rate) may not translate to Phase 3 success; dilution/financing risk can re-emerge if enrollment or endpoints disappoint.
Key entities
- companyRelmada Therapeutics
NASDAQ-listed clinical-stage biotech; NDV-01 Phase 2 data and planned Phase 3 RESCUE initiation mid-2026.
- drug_candidateNDV-01
Relmada’s candidate for high-risk non-muscle invasive bladder cancer; cited 95% complete response rate in 12-month Phase 2 data.
- clinical_programRESCUE
Planned Phase 3 registrational program scheduled to initiate mid-2026; design to be presented at AUA.
